Permits and Restrictions |
View Permits |
---|---|
Organism | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
Tissue | Spleen |
Cell Type | Hybridoma: B lymphocyte |
Product Format | frozen |
Morphology | Lymphoblast |
Culture Properties | Suspension |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Strain | CAF1 (B cell); BALB/c (myeloma) |
Shipping Information | Frozen |
Storage Conditions | liquid nitrogen vapor phase |
Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
Derivation | Mice were immunized with human peripheral blood lymphocytes. Spleen cells were fused with P3x63Ag8.U1 myeloma cells. |
---|---|
Genes Expressed | immunoglobulin; monoclonal antibody; against human T cell (human T lymphocyte); against CD3 |
Cellular Products | immunoglobulin; monoclonal antibody; against human T cell (human T lymphocyte); against CD3 |
Complete Growth Medium | The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%. |
---|---|
Subculturing |
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 105 cells/mL and maintain between 1 X 105 and 1 X 106 cells/mL.
Medium Renewal: Every 2 to 3 days |
Cryopreservation |
Complete culture medium described above supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
Culture Conditions | Temperature: 37°C |
Isotype | IgG2a |
---|
Name of Depositor | Ortho Pharmaceutical Corporation |
---|---|
U.S. Patent Number | 4,361,549 |
Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
References |
Hoffman RA, et al. Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood. Proc. Natl. Acad. Sci. USA 77: 4914-4917, 1980. PubMed: 6968909 Kung PC, Goldstein G. Complement-fixing monoclonal antibody to human T cells, and methods of preparing same. US Patent 4,361,549 dated Nov 30 1982 Tanaka Y, et al. Productive and lytic infection of human CD4+ type 1 helper T cells with macrophage-tropic human immunodeficiency virus type 1. J. Virol. 71: 465-470, 1997. PubMed: 8985372 Solomon KR, et al. The association between glycoslphosphatidylinositol-anchored proteins and hetrotrimeric G protein alpha subunits in lymphocytes. Proc. Natl. Acad. Sci. USA 93: 6053-6058, 1996. PubMed: 8650218 Hutchcroft JE, et al. Differential phosphorylation of the T lymphocyte costimulatory receptor CD28. J. Biol. Chem. 271: 13362-13370, 1996. PubMed: 8662792 Hartley D, Corvera S. Formation of c-Cb1-phosphatidylinositol 3-kinase complexes on lymphocyte membranes by a p56lck-independent mechanism. J. Biol. Chem. 271: 21939-21943, 1996. PubMed: 8702998 |